Description: Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of Duchenne. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Home Page: satellos.com
Royal Bank Plaza
Toronto,
ON
M5J 2J1
Canada
Phone:
647-660-1780
Officers
| Name | Title |
|---|---|
| Mr. Francis Gleeson B.B.A. M.B.A | Co-Founder, CEO, President & Director |
| Ms. Elizabeth Williams C.A., CPA | CFO & Corporate Secretary |
| Dr. Philip Lambert M.A., Ph.D. | Chief Scientific Officer |
| Mr. William Wasyl Jarosz | Executive Director |
| Mr. Warren Whitehead C.M.A., CPA | Head of Corporate Strategy |
| Dr. Michael Cross M.B.A., Ph.D. | Chief Business Officer |
| Dr. Michael A. Rudnicki Ph.D. | Co-Founder & Chief Discovery Officer |
| Mr. J. Robert Hall CFA | Senior Vice President of Finance & Administration |
| Mr. Michael Liggett B.Sc., Bsc. Pharm., C.A., C.P.A., CA, CPA | Strategic Advisor |
| Ms. Desiree Chan | Chief of Staff |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.8333 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |